Significant Ownership of Stonepine Capital Management, LLC
- Signature - Title
- /s/ Jon M. Plexico - Managing Member
- Location
- Bend, OR
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by Stonepine Capital Management, LLC.
Follow Filing Activity
Follow Stonepine Capital Management, LLC and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
Useful next steps after a schedule filing
Use the page below that answers the next obvious question about this reporting manager or security.
- Latest 13D/G reports to compare this manager with other current ownership disclosures.
- Latest insider ownership reports if you want insider activity alongside the beneficial ownership record.
- Latest 13F portfolio filings for broader institutional context.
- Latest investment quarter holder pages when the next step is security-level holder history.
Significant Ownership of Stonepine Capital Management, LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| QNRX | Quoin Pharmaceuticals, Ltd. | Ordinary Shares | 11% | $47,201,973 | +$3,465,711 | 3,271,100 | +7.9% | Stonepine Capital Management, LLC | 29 Jan 2026 |
| CRIS | CURIS INC | Common Stock | 9.9% | $4,468,851 | 4,025,992 | Stonepine Capital Management, LLC | 17 Mar 2026 | ||
| INAB | IN8BIO, Inc. | Common Stock | 9.9% | $1,975,660 | 1,007,990 | Stonepine Capital Management, LLC | 19 Dec 2025 | ||
| AYTU | AYTU BIOPHARMA, INC | Common Stock | 9.9% | $1,975,217 | 906,063 | Stonepine Capital Management, LLC | 30 Jun 2025 | ||
| EDSA | Edesa Biotech, Inc. | Common Stock | 9.9% | $1,636,780 | 693,551 | Stonepine Capital Management, LLC | 13 Feb 2025 | ||
| CNSP | CNS Pharmaceuticals, Inc. | Common Stock | 7.9% | $288,079 | +$97,981 | 48,827 | +52% | Stonepine Capital Management, LLC | 31 Dec 2025 |
| OPTN | OptiNose, Inc. | Common Stock | 7.8% | $7,176,688 | +$1,819,909 | 788,647 | +34% | Stonepine Capital Management, LLC | 31 Mar 2025 |
| TELA | TELA Bio, Inc. | Common Stock | 6% | $2,211,913 | 2,353,099 | Stonepine Capital Management, LLC | 31 Dec 2024 | ||
| CALC | CalciMedica, Inc. | Common Stock | 4.6% | $949,295 | -$170,674 | 628,672 | -15% | Stonepine Capital Management, LLC | 31 Mar 2025 |
| VSTM | Verastem, Inc. | Common Stock | 4.3% | $23,576,383 | -$1,441,948 | 2,670,032 | -5.8% | Stonepine Capital Management, LLC | 30 Sep 2025 |
| APRE | Aprea Therapeutics, Inc. | Common Stock | 4.3% | $418,978 | -$82,213 | 239,416 | -16% | Stonepine Capital Management, LLC | 31 Mar 2025 |
| INO | Inovio Pharmaceuticals, Inc. | Common Stock | 3.8% | $2,683,444 | -$900,721 | 1,434,997 | -25% | Stonepine Capital Management, LLC | 31 Mar 2025 |
| SRZN | Surrozen, Inc./DE | Common Stock | 3.6% | $6,531,368 | -$3,973,019 | 316,289 | -38% | Stonepine Capital Management, LLC | 31 Dec 2025 |
| KZR | Kezar Life Sciences, Inc. | Common Stock | 2.1% | $968,310 | -$1,370,578 | 156,179 | -59% | Stonepine Capital Management, LLC | 31 Dec 2025 |
Schedules 13D/G Reported by Stonepine Capital Management, LLC:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.